EUVIMEDEUVIMED entdecken
Crossref

Silicosis amelioration by chaetocin: a novel therapeutic strategy targeting the HIF1α-mediated PI3K/AKT/MMP9 pathway

Yujing Fang, Na Xu, Chao Liang, Xiaofei Hu, Xiaolong Cai, Yifan Jing, Huihui Tao, Dong Hu, Ying Bai

International Immunopharmacology · 2026-06 · 178 · 116593

DOI: 10.1016/j.intimp.2026.116593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-06. Verfasst von Yujing Fang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Industrial Dust Deep Reduction and Occupational Health and Safety of Anhui Higher Education Institutes, School of Medicine, Anhui U…. Hauptthemen laut MEDLINE: Silicosis, Hypoxia-Inducible Factor 1, alpha Subunit, Piperazines, Anti-Inflammatory Agents. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Anhui University of Science and Technology, National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Silicosis, a debilitating occupational lung fibrosis caused by chronic silica dust inhalation, currently lacks effective therapeutic interventions, and its underlying molecular pathogenesis remains incompletely understood. To address this critical gap, we employed an integrated strategy combining bioinformatics, network pharmacology, and experimental validation to systematically identify novel therapeutic targets and candidate compounds for silicosis. Through analysis of silicosis-related differentially expressed genes from the GEO database and in silico prediction using the cMap platform, we identified the natural product chaetocin as a promising candidate. In a murine model of silicosis, chaetocin administration significantly improved pulmonary function and alleviated lung inflammation and collagen deposition. Notably, at a dose of 1 mg/kg, chaetocin demonstrated superior efficacy to pirfenidone, a current standard-of-care agent. In vitro studies further confirmed that chaetocin effectively attenuated silica-triggered macrophage inflammatory responses, apoptosis, and reactive oxygen species (ROS) production, while also suppressing fibroblast migration and activation. Mechanistic investigations revealed that chaetocin exerts its anti-inflammatory and anti-fibrotic effects by directly targeting HIF1α, thereby inhibiting the downstream PI3K/AKT/MMP9 signaling axis. Collectively, our findings establish chaetocin as a novel naturally-derived therapeutic candidate with significant potential for the treatment of silicosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SilicosisHypoxia-Inducible Factor 1, alpha SubunitPiperazinesAnti-Inflammatory AgentsAnimalsSignal TransductionProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMiceMatrix Metalloproteinase 9HumansLungMaleReactive Oxygen SpeciesMice, Inbred C57BLDisease Models, AnimalPyridonesApoptosis

Stichwörter der Autor:innen

ChaetocinFibrosisInflammationSignaling pathwaySilicosis

Substanzen

Hypoxia-Inducible Factor 1, alpha SubunitProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinaseschaetocinMatrix Metalloproteinase 9PiperazinesAnti-Inflammatory AgentsHif1a protein, mouseMmp9 protein, mouseReactive Oxygen Species

Autor:innen und Institutionen

  • Key Laboratory of Industrial Dust Deep Reduction and Occupational Health and Safety of Anhui Higher Education Institutes, School of Medicine, Anhui University of Science and Technology, Huainan City, China; Anhui Provin…
  • Key Laboratory of Industrial Dust Deep Reduction and Occupational Health and Safety of Anhui Higher Education Institutes, School of Medicine, Anhui University of Science and Technology, Huainan City, China; The First Af…

Förderung

  • Anhui University of Science and Technology
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Anhui Province

Zitieren

APA

Fang, Y., Xu, N., Liang, C., Hu, X., Cai, X., Jing, Y., Tao, H., Hu, D., & Bai, Y. (2026). Silicosis amelioration by chaetocin: a novel therapeutic strategy targeting the HIF1α-mediated PI3K/AKT/MMP9 pathway. International Immunopharmacology, 178, 116593. https://doi.org/10.1016/j.intimp.2026.116593

Vancouver

Fang Y, Xu N, Liang C, Hu X, Cai X, Jing Y, et al. Silicosis amelioration by chaetocin: a novel therapeutic strategy targeting the HIF1α-mediated PI3K/AKT/MMP9 pathway. International Immunopharmacology. 2026;178:116593. doi:10.1016/j.intimp.2026.116593

BibTeX
@article{Fang2026,
  author = {Fang, Yujing and Xu, Na and Liang, Chao and Hu, Xiaofei and Cai, Xiaolong and Jing, Yifan and Tao, Huihui and Hu, Dong and Bai, Ying},
  title = {Silicosis amelioration by chaetocin: a novel therapeutic strategy targeting the HIF1α-mediated PI3K/AKT/MMP9 pathway},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {178},
  pages = {116593},
  doi = {10.1016/j.intimp.2026.116593}
}
Kostenlos starten →